Orlando, Fla.—In a huge observational study investigating the use of direct oral anticoagulants (DOACs) in adults with non-valvular atrial fibrillation (NVAF), apixaban was associated with a significantly lower cumulative incidence of stroke/systemic embolism and major bleeding compared with two other FDA-approved DOACs.
The study, which was presented at the American College of Cardiology (ACC) 2018 annual meeting, analyzed hospital claims data covering 162,707 NVAF